Heidelberg Pharma AG
WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit
DGAP-News: WILEX AG / Key word(s): Conference PRESS RELEASE WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit – Heidelberg Pharma shortlisted for World ADC Award Munich, Germany, 20 September 2017 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that its subsidiary, Heidelberg Pharma Research GmbH, Ladenburg, Germany, will present at the 8th Annual World ADC Summit taking place on 20-22 September in San Diego, CA, USA. This annual summit is expected to draw record attendance from over 650 companies including large and small pharma, biotech, academia as well as CROs, CMOs and industry suppliers that cover every element of Antibody Drug Conjugate (ADC) development. The World ADC Summit organizes cutting-edge science and transformative insights. Further information can be found at: http://worldadc-usa.com. Antibody Targeted Amanitin Conjugates (ATACs): Expanding the ADC Landscape with a New Payload Targeting RNA Polymerase II Heidelberg Pharma will discuss how Antibody Targeted Amanitin Conjugates (ATACs) represent a new class of ADCs using the payload Amanitin, which inhibits RNA polymerase II, a novel mode of action in oncology therapy. The presentation will include improvements in the technology and an update of the HDP-101 development, the first Amanitin loaded ADC directed against B-cell maturation antigens (BCMA) and scheduled to enter Phase I trials in Multiple Myeloma by the end of 2018. Additionally, Heidelberg Pharma has been nominated a finalist for the 4th Annual World ADC Awards in the category “Best New Drug Developer”. The Award’s ceremony takes place on 21 September 2017 in the Bel Aire Ballroom of the Sheraton San Diego Marina at 7:15 PM (CDT). About Heidelberg Pharma’s proprietary ATAC technology About WILEX and Heidelberg Pharma
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
20.09.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | WILEX AG |
Grillparzerstr. 18 | |
81675 München | |
Germany | |
Phone: | +49 (0)89 41 31 38 – 0 |
Fax: | +49 (0)89 41 31 38 – 99 |
E-mail: | info@wilex.com |
Internet: | www.wilex.com |
ISIN: | DE000A11QVV0 |
WKN: | A11QVV |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |